<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223613</url>
  </required_header>
  <id_info>
    <org_study_id>DIPP19942014</org_study_id>
    <secondary_id>JDRF File # 4-1999-731</secondary_id>
    <nct_id>NCT00223613</nct_id>
  </id_info>
  <brief_title>Intranasal Insulin for Prevention of Type 1 Diabetes</brief_title>
  <official_title>Intranasal Insulin for Prevention of Type 1 Diabetes in Children Carrying Increased HLA-Conferred Genetic Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <brief_summary>
    <textblock>
      Children born in Turku, Oulu and Tampere university cities in Finland are screened at birth
      for HLA alleles that carry increased risk to or protection from development of type 1
      diabetes. Children carrying increased risk are followed at 3-12-month intervals for
      development of diabetes-associated autoantibodies. Children having at least two types of
      autoantibodies (of the four measured) in at least two consecutively drawn samples are
      randomized to receive daily intranasal insulin or placebo in a double-blinded 1:1 trial.
      Hypothesis is that intranasal insulin delays or prevents development of clinical type 1
      diabetes. The primary outcome measure is development of clinical diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children born in Turku, Oulu and Tampere university cities in Finland are screened at birth
      for the HLA-DQB1 and DQA1 alleles that carry increased risk to or protection from development
      of type 1 diabetes. Children carrying increased risk are followed at 3-month intervals until
      2 years of age and then at 6-12-month intervals until,15 years of age for development of
      diabetes-associated autoantibodies (autoantibodies against islet cells, insulin, glutamic
      acid decarboxylase and IA-2 protein). Children having at least two types of autoantibodies of
      the four measured in at least two consecutively drawn samples are randomized to receive daily
      intranasal insulin or placebo in a double-blinded 1:1 trial. Hypothesis is that intranasal
      insulin delays or prevents development of clinical type 1 diabetes. The primary outcome
      measure is development of clinical diabetes, but serum concentrations of autoantibodies,
      responses to intravenous glucose tolerance test and possible side effects of therapy are also
      closely monitored.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 1997</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of clinical type 1 diabetes</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and concentration in serum of diabetes-associated autoantibodies (ICA, IAA, GADA and IA-2A)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to intravenous glucose tolerance test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possible side effects of therapy including hypoglycemia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum metabolite patterns (metabolomics)</measure>
  </secondary_outcome>
  <enrollment>240</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daily intranasal administration of insulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children carrying HLA-conferred genetic risk for developing type 1 diabetes

          -  have had at least two types of autoantibodies of ICA, IAA, GADA and IA-2A in at least
             two consecutive blood samples drawn at least 3 months apart

          -  age at least one year

        Exclusion Criteria:

          -  severe other disease

          -  age above 15 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olli G Simell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku, Turku, Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olli G Simell, MD, PhD</last_name>
    <phone>+358-2-313-2466</phone>
    <email>olli.simell@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tuula T Simell, MPH, PhD</last_name>
    <phone>+358-2-313-3427</phone>
    <email>tuula.simell@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, University of Turku</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuula T Simell, MPH, PhD</last_name>
      <phone>+358-2-313-3427</phone>
      <email>tuula.simell@utu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Birgitta Nurmi, RN</last_name>
      <phone>+358-2-313-2465</phone>
      <email>birgitta.nurmi@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Kirsti Näntö-Salonen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Kupila A, Sipilä J, Keskinen P, Simell T, Knip M, Pulkki K, Simell O. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults. Diabetes Metab Res Rev. 2003 Sep-Oct;19(5):415-20.</citation>
    <PMID>12951650</PMID>
  </reference>
  <reference>
    <citation>Keskinen P, Korhonen S, Kupila A, Veijola R, Erkkilä S, Savolainen H, Arvilommi P, Simell T, Ilonen J, Knip M, Simell O. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia. 2002 Dec;45(12):1639-48. Epub 2002 Oct 30.</citation>
    <PMID>12488953</PMID>
  </reference>
  <reference>
    <citation>Kupila A, Keskinen P, Simell T, Erkkilä S, Arvilommi P, Korhonen S, Kimpimäki T, Sjöroos M, Ronkainen M, Ilonen J, Knip M, Simell O. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children. Diabetes. 2002 Mar;51(3):646-51.</citation>
    <PMID>11872662</PMID>
  </reference>
  <reference>
    <citation>Hermann R, Mantere J, Lipponen K, Veijola R, Soltesz G, Otonkoski T, Simell O, Knip M, Ilonen J. Lack of association of PAX4 gene with type 1 diabetes in the Finnish and Hungarian populations. Diabetes. 2005 Sep;54(9):2816-9.</citation>
    <PMID>16123375</PMID>
  </reference>
  <reference>
    <citation>Kukko M, Toivonen A, Kupila A, Korhonen S, Keskinen P, Veijola R, Virtanen SM, Ilonen J, Simell O, Knip M. Familial clustering of beta-cell autoimmunity in initially non-diabetic children. Diabetes Metab Res Rev. 2006 Jan-Feb;22(1):53-8.</citation>
    <PMID>16100734</PMID>
  </reference>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 18, 2006</last_update_submitted>
  <last_update_submitted_qc>September 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2006</last_update_posted>
  <keyword>diabetes</keyword>
  <keyword>juvenile diabetes</keyword>
  <keyword>insulin deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

